

## United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/622,544	10/13/2000	Sarkis Barret Kalindjian	40283/183	8561
22428	7590 04/23/2003			. •
FOLEY AND LARDNER SUITE 500 3000 K STREET NW			EXAMINER .	
			KIFLE, I	BRUCK
WASHINGTON, DC 20007			ART UNIT	PAPER NUMBER
			1624	91
			DATE MAILED: 04/23/2003	

Please find below and/or attached an Office communication concerning this application or proceeding.



## Office Action Summary

Application No. **09/622,544** 

Applicant(s)

Kalindjian et al.

Examiner

Bruck Kifle, Ph.D.

Art Unit 1624



_	The MAILING DATE of this communication appears	on the cover sheet with the correspondence address			
	for Reply				
THE N		TO EXPIRE MONTH(S) FROM  no event, however, may a reply be timely filed after SIX (6) MONTHS from the			
- If the p - If NO p - Failure - Any re	g date of this communication.  period for reply specified above is less than thirty (30) days, a reply within th  period for reply is specified above, the maximum statutory period will apply a  to reply within the set or extended period for reply will, by statute, cause th  eply received by the Office later than three months after the mailing date of t  d patent term adjustment. See 37 CFR 1.704(b).	and will expire SIX (6) MONTHS from the mailing date of this communication. he application to become ABANDONED (35 U.S.C. § 133),			
Status					
1) 💢	Responsive to communication(s) filed on Mar 20, 2	2003 .			
2a) 🗌	This action is <b>FINAL</b> . 2b) 💢 This act	tion is non-final.			
3) 🗆	closed in accordance with the practice under Ex pair	except for formal matters, prosecution as to the merits is arte Quayle, 1935 C.D. 11; 453 O.G. 213.			
	ition of Claims				
4) 💢	Claim(s) 1, 3-5, 8, 13-27, and 29-35	is/are pending in the application.			
Δ	la) Of the above, claim(s) <u>3-5, 8, 13-27, and 29-35</u>	is/are withdrawn from consideration.			
5) 🗆	Claim(s)	is/are allowed.			
6) 💢	Claim(s) 1	is/are rejected.			
	Claim(s)				
8) 🗆	Claims	are subject to restriction and/or election requirement.			
	ation Papers				
9) 🗆	The specification is objected to by the Examiner.	·			
10)	10) ☐ The drawing(s) filed on is/are a) ☐ accepted or b) ☐ objected to by the Examiner.				
	Applicant may not request that any objection to the d	lrawing(s) be held in abeyance. See 37 CFR 1.85(a).			
11)	The proposed drawing correction filed on	is: a) $\square$ approved b) $\square$ disapproved by the Examiner.			
	If approved, corrected drawings are required in reply t	to this Office action.			
12)	The oath or declaration is objected to by the Exami	iner.			
Priority	under 35 U.S.C. §§ 119 and 120				
13) 🗌	13) Acknowledgement is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).				
a)	a) □ All b) □ Some* c) □ None of:				
,	1. Certified copies of the priority documents have been received.				
:	2. Certified copies of the priority documents have been received in Application No				
	application from the International Burea				
_	ee the attached detailed Office action for a list of the				
_	Acknowledgement is made of a claim for domestic				
-	a) The translation of the foreign language provisional application has been received.				
_	Acknowledgement is made of a claim for domestic	priority under 35 U.S.C. §§ 120 and/or 121.			
Attachme	ent(s) ptice of References Cited (PTO-892)	41 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1			
	otice of Draftsperson's Patent Drawing Review (PTO-948)	4) Interview Summary (PTO-413) Paper No(s)  5) Notice of Informal Patent Application (PTO-152)			
	formation Disclosure Statement(s) (PTO-1449) Paper No(s).	8) Other:			

Application/Control Number: 09/622,544

Art Unit: 1624

Applicant's remarks filed 3/20/03 have been received and reviewed. Claims 1, 3-5, 8, 13-27 and 29-35 are pending in this application.

Page 2

Note that compounds, corresponding compositions, a method of use and a process of making that are of the **same** scope are considered to form a single inventive concept under PCT Rule 13.1, 37 CFR 1.475(d). The instant claims are still not of the same scope.

Claims 3-5, 8, 13-27 and 29-35 are withdrawn from consideration because art was found (see MPEP 803.02.)

Applicants are also advised of MPEP 803.02 Restriction - Markush Claims [R - 2], fourth paragraph, where is stated;

"As an example, in the case of an application with a Markush - type claim drawn to the compound C - R, wherein R is a radical selected from the group consisting of A, B, C, D, and E, the examiner may require a provisional election of a single species, CA, CB, CC, CD, or CE. The Markush - type claim would then be examined fully with respect to the elected species and any species considered to be clearly unpatentable over the elected species. If on examination the elected species is found to be anticipated or rendered obvious by prior art, the Markush - type claim and claims to the elected species shall be rejected, and claims to the non - elected species would be held withdrawn from further consideration. As in the prevailing practice, a second action on the rejected claims would be made final." (emphasis added).

Application/Control Number: 09/622,544 Page 3

Art Unit: 1624

## Claim Rejections - 35 USC § 102

The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action.

Claim 1 is rejected under 35 U.S.C. 102(b) as being anticipated by Schohe et al. (US 5,453,437). The claims read on the compound of examples 36 and 37 (see Table 1, columns 29-30 and the definitions of DMS and DES as N,N-dimethyl sulphamoyl and N,N-diethyl sulphamoyl, respectively, which correspond to instant Z as -S(O)<sub>2</sub>-NMe<sub>2</sub> and -S(O)<sub>2</sub>-NEt<sub>2</sub>).

Claim 1 is rejected under 35 U.S.C. 102(b) as being anticipated by Moreau et al. (Annales Pharmaceutiques Françaises (1981), 39(3), 283-90). The claim reads on the compound of RN 74254-72-1 (see CAS abstract and structure).

## Claim Rejections - 35 USC § 103

The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action.

Claim 1 is rejected under 35 U.S.C. 103(a) as being unpatentable over Schohe et al. (US 5,453,437). The reference teaches a generic group of compounds which embraces applicants' claimed compounds (See col. 1, line 20 to col. 3, line 51), compounds of formula (I) and definitions for B and -X-A). The claims differ from the reference by reciting a more limited genus than the reference. However, it would have been obvious to one having ordinary skill in the art at the time of the invention to select any of the species of the genus taught by the reference, including those instantly claimed, because the skilled chemist would have the

Application/Control Number: 09/622,544 Page 4

Art Unit: 1624

reasonable expectation that any of the species of the genus would have similar properties and, thus, the same use as taught for the genus as a whole. One of ordinary skill in the art would have been motivated to select the claimed compounds from the genus in the reference since such compounds would have been suggested by the reference as a whole. It has been held that a prior art disclosed genus of useful compounds is sufficient to render prima facie obvious a species falling within a genus. *In re Susi*, 440 F.2d 442, 169 USPQ 423, 425 (CCPA 1971), followed by the Federal Circuit in *Merck & Co. v. Biocraft Laboratories*, 847 F.2d 804, 10 USPQ 2d 1843, 1846 (Fed. Cir. 1989).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Bruck Kifle whose telephone number is (703) 305-4484.

The fax phone number for this Group is (703) 308-4556 or (703) 305-3592. Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the Group receptionist whose telephone number is (703) 308-1235.

April 22, 2003

Bruck Kifle /
Primary Examiner
Art Unit 1624